SUPPLEMENTARY APPENDIX 1: SYSTEMATIC REVIEW METHODS

Search Strategy Papers were identified by searches of EMBASE and Medline (1966 to 26 August 2010) with the search terms (("mild cognitive impairment" OR MCI OR preclinical OR prodrom* OR "early stage") AND (pathology OR neuropath* OR clinicopath*)). Articles published online ahead of print, secondary references and review articles were also retrieved. There were no limits on the study population (clinic vs. population-based) or the case definition of MCI, if clearly described and representing an intermediate cognitive state.

Exclusion Criteria As the aim was to include all published papers that had investigated the neuropathological profile of MCI, papers where MCI and NCI or MCI and dementia groups had been combined for analysis or where MCI had progressed to dementia at time of death were excluded. Further, papers where case selection criteria combined neuropsychological and neuropathological thresholds were also excluded as the aim of the review was to assess whether there are neuropathological differences across different cognitive profiles, including NCI, MCI and dementia (1-22). Full details of these studies are outlined in Supplementary Table 3. Where MCI occurred within the framework of other diseases, for example psychiatric disorders (depression, and schizophrenia) or Parkinson’s disease (PD), these papers were excluded. Other restrictions included studies on humans and in English language.

Search Outcome The initial search yielded 2,808 articles. Titles and abstracts were then assessed for inclusion by two authors (BS and DH). From the electronic search 46 articles meet inclusion criteria and 116 were identified from other sources including reference lists of included articles and reviews. Therefore, a total of 162 articles were identified for inclusion.

RESULTS

Description of Studies One hundred and sixty two articles were identified. Of these, 46 came from the Religious Orders Study and 5 from the Nun Study. Seventy-six came from university affiliated dementia research centres including: 4 from universities in California, 20 from the University of Geneva, 30 from the University of Kentucky, 18 from Washington University, 3 from the University of Miami and 1 from the University of Leipzig. Thirteen were from cohort studies, 2 were from hospital based samples, 18 from academic affiliates of the Mount Sinai School of Medicine (New York, NY) and 2 from other sources (not specified). A description of the included papers is outlined in Supplementary Table 1. Diversity of sample source across studies raises questions of comparability. Indeed, where clinical and community cohorts have been compared the spectrum of pathologies in NCI, MCI and dementia groups are found to differ across the two samples (23).

Sample Demographics The demographic profile of MCI samples varies considerably across studies. Samples range from young-old to oldest-old (range of means for MCI samples: 68.0-98.6 years). On average, educational attainment was high (range of means for MCI samples: 13.0 years-college graduate), however, there were a considerable number of studies (n=99) where education attainment was not reported. Generally, samples were similar in general cognitive ability as indicated by mean Mini Mental State Examination (MMSE) score (Mean Range: 22.1-28.5).

References

1. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Increased expression of RXRalpha in dementia: an early harbinger for the cholesterol dyshomeostasis? Molecular Neurodegeneration. 2010;5:36.

2. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. Brain Research. 2010 Mar 8;1318:167-77.

3. Attems J, Jellinger KA. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol. 2006 Nov-Dec;25(6):265-71.

4. Berg L, McKeel DW, Jr., Miller JP, Storandt M, Rubin EH, Morris JC, et al. Clinicopathologic Studies in Cognitively Healthy Aging and Alzheimer Disease: Relation of Histologic Markers to Dementia Severity, Age, Sex, and Apolipoprotein E Genotype. Archives of Neurology. 1998 March 1, 1998;55(3):326-35.

5. Bradley MA, Xiong-Fister S, Markesbery WR, Lovell MA. Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiology of Aging. 2010;Epub ahead of print.

6. Gastard MC, Troncoso JC, Koliatsos VE. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol. 2003 Sep;54(3):393-8.

7. Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW, Jr., Rubin EH, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology. 2001 Feb 13;56(3):361-7.

8. Iacono D, Markesbery WR, Gross M, Pletnikova O, Rudow G, Zandi P, et al. The Nun Study: Clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology. 2009 September 1, 2009;73(9):665-73.

9. Iacono D, O'Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, et al. Neuronal hypertrophy in asymptomatic Alzheimer disease. Journal of Neuropathology & Experimental Neurology. 2008 Jun;67(6):578-89.

10. Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res. 2007 Apr-May;32(4-5):845-56.

11. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Annals of Neurology. 2005;58(5):730-5.

12. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Archives of Neurology. 2006 Jan;63(1):38-46.

13. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease. Archives of Neurology. 2001 September 1, 2001;58(9):1395-402.

14. Riudavets MA, Iacono D, Resnick SM, O'Brien R, Zonderman AB, Martin LJ, et al. Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Neurobiology of Aging. 2007;28(10):1484-92.

15. Sager KL, Wuu J, Leurgans SE, Rees HD, Gearing M, Mufson EJ, et al. Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Annals of Neurology. 2007 Dec;62(6):640-7.

16. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW, Jr., Cohen ML, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. Journal of Alzheimers Disease. 2010 Jan;19(1):363-72.

17. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular Pathology in Alzheimer Disease: Correlation of Cerebral Amyloid Angiopathy and Arteriosclerosis/Lipohyalinosis with Cognitive Decline. Journal of Neuropathology & Experimental Neurology. 2003;62(12):1287-301.

18. Webster B, Hansen L, Adame A, Crews L, Torrance M, Thal L, et al. Astroglial Activation of Extracellular-Regulated Kinase in Early Stages of Alzheimer Disease. Journal of Neuropathology & Experimental Neurology. 2006;65(2):142-51.

19. Wang W-X, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, et al. The Expression of MicroRNA miR-107 Decreases Early in Alzheimer's Disease and May Accelerate Disease Progression through Regulation of {beta}-Site Amyloid Precursor Protein-Cleaving Enzyme 1. The Journal of Neuroscience. 2008 January 30, 2008;28(5):1213-23.

20. Woltjer RL, Duerson K, Fullmer JM, Mookherjee P, Ryan AM, Montine TJ, et al. Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol. 2010 Jul;69(7):667-76.

21. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Archives of Neurology. 2006 May;63(5):674-81.

22. Jicha GA, Petersen RC, Knopman DS, Boeve BF, Smith GE, Geda YE, et al. Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment. J Neuropathol Exp Neurol. 2006 Jun;65(6):602-9.

23. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 2009;18(3):691-701.